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Purpose of the study
Study of the natural course of MC in HIV-1 (+) treatment-
naïve patients at presentation, who will be followed-up
regularly to delineate the time course of appearance and
evolution or possible disappearance of MC in association
with clinical and laboratory indices, therapy and clinical
outcome (development of non-Hodgkin's lymphoma
[NHL]).
Methods
Currently diagnosed patients (n = 67, men = 58, women
= 9, mean age = 39.17 years, Greeks = 55, foreigners = 12)
at their first staging examination were tested for the pres-
ence of MC. All participating patients will be followed-up
every 4 months.
Summary of results
MC was found at presentation in four, in two in the first,
second and third follow-up, and in the fourth and fifth
follow-up, in one. Only in one patient, who was MC (+)
in the first three tests, was CD8 lymphocytosis diagnosed.
In the rest of the MC (+) patients, no evidence of NHL was
found so far.
Conclusion
MC has been found to occur in 27% of HIV-1 (+) patients
(1996–1997) [1], but its prevalence has declined during
the HAART era (12/2003–07/2004) to 7.5% [2]. It is evi-
dent in the present study that MC is rare due possibly to
earlier diagnosis and the use of HAART, but the long-term
follow-up will clarify the phenomenon and give medical
evidence as to whether the presence of MC is an indication
for the initiation of treatment.
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